SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.11-2.1%Nov 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RCMac who wrote (5374)1/9/2002 12:55:22 PM
From: Biomaven  Read Replies (1) of 52153
 
RCM,

A strong defense to that "insider information" charge is that an independent outsider (BMY) had (presumably) the same information as the insiders and it did not deter them from making the purchase. My guess is that the prior communications from the FDA were pretty routine stuff - certainly BMY would have examined all of it.

I suspect the FDA changed their minds about this study, which is consonant with the early reports that there was a struggle within the FDA about the refusal to file.

Of course if IMCL concealed stuff from BMY, then it's not only the class action lawyers that will be busy. <g>

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News